Abstract: 5-FU can down-regulate expression of miRNA-199a-5p, then activate the endoplasmic reticulum stress ATF6 pathway, increase the expression of GRP78 and ATF6, affect the function of cardiomyocytes, and induce cardiac toxicity.
Introduction
Fluorouracil (5-FU) is a widely used chemotherapeutic agent for treating various cancers, including colorectal and breast cancers. However, its clinical application is significantly limited by its cardiotoxicity, which can lead to severe heart failure. While oxidative and endoplasmic reticulum (ER) stress have been implicated, the precise molecular mechanisms remain poorly understood. This study investigates the role of miRNA-199a-5p and its regulation of the ATF6 signaling pathway in 5-FU-induced heart damage.
Methods
The researchers utilized both in vitro and in vivo models. Primary cardiomyocytes from neonatal rats were treated with 5-FU to observe cellular effects, while Sprague Dawley (SD) rats were used to model systemic cardiotoxicity. Key techniques included:
- Molecular Assays: Dual-luciferase reporter assays to confirm miRNA-199a-5p binding to ATF6, and Western blotting/qRT-PCR for protein and RNA quantification.
- Functional Assessment: Echocardiography to measure ejection fraction and fractional shortening in rats.
- Biochemical Analysis: Measurement of SOD, GSH/GSSG, and LDH to assess oxidative stress.
- Histology: H&E staining to evaluate tissue-level damage.
Results
5-FU Induces Dose-Dependent Cardiotoxicity
Treatment with 5-FU led to a significant reduction in cardiomyocyte viability and an increase in oxidative stress markers. Specifically, 5-FU decreased superoxide dismutase (SOD) activity and the GSH/GSSG ratio while increasing extracellular lactate dehydrogenase (LDH) levels.
In animal models, 5-FU administration resulted in impaired left ventricular function, characterized by reduced ejection fraction and fractional shortening.
Pathological Damage and the miRNA-199a-5p/ATF6 Axis
Histological examination of heart tissue revealed inflammatory cell infiltration and focal necrosis in 5-FU-treated rats. These changes were quantified using a pathology injury score, which increased significantly with higher doses of 5-FU.
Mechanistically, the study found that 5-FU downregulates miRNA-199a-5p. This microRNA normally acts as a negative regulator of the ATF6 gene. Its depletion allows for the activation of the ATF6 signaling pathway, triggering a cascade of ER stress proteins (such as GRP78 and CHOP) that ultimately lead to cell death.
Discussion
The findings highlight miRNA-199a-5p as a critical protective factor against 5-FU-induced cardiotoxicity. By targeting the ATF6 pathway, this microRNA mitigates ER stress and oxidative damage. Importantly, restoring miRNA-199a-5p levels using cationic liposomes was shown to improve cardiac function and reduce tissue necrosis in rats, suggesting a potential therapeutic avenue. Future research should focus on targeted delivery to the heart to avoid interfering with 5-FU's anti-tumor efficacy in other tissues and validating these findings in human clinical settings.
Summary updated